Drugs / NCP-IL-22BP mRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07562815 | Apr 2026 → Apr 2027 expected | cancer | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCP-IL-22BP mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07562815 ↗ |
| Known as | Non-Cationic Peptide-IL-22BP mRNA | “Non-Cationic Peptide-IL-22BP mRNA (NCP-IL-22BP mRNA)” NCT07562815 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA encoding interleukin-22 binding protein (IL-22BP)” NCT07562815 ↗ |
| Route | Other | “administered by intratumoral injection” NCT07562815 ↗ |